Montefiore Medical Center & Albert Einstein College of Medicine
Welcome,         Profile    Billing    Logout  
 1 Trial 
13 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Verma, Amit
NCI-2009-01173, NCT00843882: Lenalidomide With or Without Epoetin Alfa in Treating Patients With Myelodysplastic Syndrome and Anemia

Active, not recruiting
3
247
US
Bone Marrow Biopsy, Biopsy of Bone Marrow, Biopsy, Bone Marrow, Epoetin Alfa, EPO, Epoetin alfa-epbx, Epogen, Eprex, Procrit, Retacrit, Laboratory Biomarker Analysis, Lenalidomide, CC-5013, CC5013, CDC 501, Revlimid
National Cancer Institute (NCI)
Anemia, Chronic Myelomonocytic Leukemia, de Novo Myelodysplastic Syndrome, Myelodysplastic Syndrome
07/19
09/24
CA-4948-102, NCT04278768: Dose Escalation/ Expansion Study of CA-4948 as Monotherapy in Patients With AML or MDS

Recruiting
1/2
366
Europe, US, RoW
Emavusertib, CA-4948, Venetoclax
Curis, Inc.
Acute Myelogenous Leukemia, Myelodysplastic Syndrome
04/26
04/26
Shastri, Aditi
NCT03258931: Study of Crenolanib vs Midostaurin Following Induction Chemotherapy and Consolidation Therapy in Newly Diagnosed FLT3 Mutated AML

Recruiting
3
510
US
Crenolanib, Crenolanib besylate, Midostaurin, Cytarabine, Duanorubicin
Arog Pharmaceuticals, Inc.
Newly Diagnosed FLT3 Mutated AML
11/22
11/24
SELECT MDS-1, NCT04797780 / 2020-004528-40: Tamibarotene Plus Azacitidine in Participants With Newly Diagnosed RARA-positive Higher-Risk Myelodysplastic Syndrome

Recruiting
3
550
Europe, Canada, US, RoW
Tamibarotene, SY-1425, Placebo, Azacitidine
Syros Pharmaceuticals
Myelodysplastic Syndromes
11/24
02/29
NCI-2021-02246, NCT04817241: Testing Oral Decitabine and Cedazuridine (ASTX727) in Combination With Venetoclax for Higher-Risk Acute Myeloid Leukemia Patients

Active, not recruiting
1/2
55
US
Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Bone Marrow Aspiration and Biopsy, Cytarabine, .beta.-Cytosine arabinoside, 1-.beta.-D-Arabinofuranosyl-4-amino-2(1H)pyrimidinone, 1-.beta.-D-Arabinofuranosylcytosine, 1-Beta-D-arabinofuranosyl-4-amino-2(1H)pyrimidinone, 1-Beta-D-arabinofuranosylcytosine, 1.beta.-D-Arabinofuranosylcytosine, 2(1H)-Pyrimidinone, 4-Amino-1-beta-D-arabinofuranosyl-, 2(1H)-Pyrimidinone, 4-amino-1.beta.-D-arabinofuranosyl-, Alexan, Ara-C, ARA-cell, Arabine, Arabinofuranosylcytosine, Arabinosylcytosine, Aracytidine, Aracytin, Aracytine, Beta-Cytosine Arabinoside, CHX-3311, Cytarabinum, Cytarbel, Cytosar, Cytosine Arabinoside, Cytosine-.beta.-arabinoside, Cytosine-beta-arabinoside, Erpalfa, Starasid, Tarabine PFS, U 19920, U-19920, Udicil, WR-28453, Daunorubicin, Daunomycin, Daunorrubicina, DNR, Leukaemomycin C, Rubidomycin, Rubomycin C, Decitabine and Cedazuridine, ASTX727, C-DEC, CDA Inhibitor E7727/Decitabine Combination Agent ASTX727, Cedazuridine/Decitabine Combination Agent ASTX727, Cedazuridine/Decitabine Tablet, DEC-C, Inqovi, Venetoclax, ABT-0199, ABT-199, ABT199, GDC-0199, RG7601, Venclexta, Venclyxto
National Cancer Institute (NCI)
Acute Myeloid Leukemia
08/24
08/24
NCT05986240: Danvatirsen Monotherapy Followed by Combination With Venetoclax in Relapsed/Refractory MDS & AML

Recruiting
1
24
US
Danvatirsen, AZD9150, Danvatirsen + Venetoclax, Venclexta
Montefiore Medical Center, M.D. Anderson Cancer Center, Flamingo Therapeutics NV
AML/MDS, Acute Myeloid Leukemia, Myelodysplastic Syndromes
10/25
07/28
Victor, Joel
SELECT MDS-1, NCT04797780 / 2020-004528-40: Tamibarotene Plus Azacitidine in Participants With Newly Diagnosed RARA-positive Higher-Risk Myelodysplastic Syndrome

Recruiting
3
550
Europe, Canada, US, RoW
Tamibarotene, SY-1425, Placebo, Azacitidine
Syros Pharmaceuticals
Myelodysplastic Syndromes
11/24
02/29
SY-1425-202, NCT04905407: Tamibarotene Plus Venetoclax/Azacitidine in Participants With Newly Diagnosed AML

Recruiting
2
95
Europe, US
Tamibarotene, Venetoclax, Venclexta, Azacitidine, Vidaza
Syros Pharmaceuticals
Acute Myeloid Leukemia
04/28
04/28
AUGMENT-101, NCT04065399 / 2020-004104-34: A Study of Revumenib in R/R Leukemias Including Those With an MLL/KMT2A Gene Rearrangement or NPM1 Mutation

Calendar Jan 2024 - Dec 2024: Market entry for acute leukemias
Hourglass Feb 2024 - Mar 2024 : Q1'24 - PDUFA date from FDA for R/R KMT2Ar acute leukemia
Jul 2023 - Sep 2023: Data from AUGMENT-101 trial for r/r AML
Checkmark Updated data from P1 portion of P1/2 AUGMENT-101 trial for AML
Dec 2022 - Dec 2022: Updated data from P1 portion of P1/2 AUGMENT-101 trial for AML
More
Recruiting
1/2
413
Europe, Canada, US, RoW
revumenib, SNDX-5613, cobicistat
Syndax Pharmaceuticals, Syndax Pharmaceuticals, Inc
Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Mixed Lineage Acute Leukemia, Mixed Phenotype Acute Leukemia, Acute Leukemia of Ambiguous Lineage
12/24
12/24
ALPHA-2, NCT04416984: Safety and Efficacy of ALLO-501A Anti-CD19 Allogeneic CAR T Cells in Adults With Relapsed/Refractory Large B Cell Lymphoma, Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma (ALPHA2)

Recruiting
1/2
160
Europe, Canada, US, RoW
ALLO-501A, ALLO-647, Fludarabine, Cyclophosphamide
Allogene Therapeutics
Relapsed or Refractory Large B Cell Lymphoma, Relapsed or Refractory Chronic Lymphocytic Leukemia, Relapsed or Refractory Small Lymphocytic Lymphoma
01/25
05/29
NCT05225584: Safety, PK, PD, Clinical Activity of KT-333 in Adult Patients With Refractory Lymphoma, Large Granular Lymphocytic Leukemia, Solid Tumors

Recruiting
1
120
US
KT-333
Kymera Therapeutics, Inc.
Non Hodgkin Lymphoma (NHL), Peripheral T-cell Lymphoma (PTCL), Cutaneous T-Cell Lymphoma (CTCL), Large Granular Lymphocytic Leukemia (LGL-L), T-cell Prolymphocytic Leukemia (T-PLL), Solid Tumors
02/25
03/25
ANTLER, NCT04637763: CRISPR-Edited Allogeneic Anti-CD19 CAR-T Cell Therapy for Relapsed/Refractory B Cell Non-Hodgkin Lymphoma

Recruiting
1
72
US, RoW
CB-010, Cyclophosphamide, Fludarabine
Caribou Biosciences, Inc.
Lymphoma, Non-Hodgkin, Relapsed Non Hodgkin Lymphoma, Refractory B-Cell Non-Hodgkin Lymphoma, Non Hodgkin Lymphoma, Lymphoma, B Cell Lymphoma, B Cell Non-Hodgkin's Lymphoma
08/25
09/25
Sutamtewagul, Grerk
SELECT MDS-1, NCT04797780 / 2020-004528-40: Tamibarotene Plus Azacitidine in Participants With Newly Diagnosed RARA-positive Higher-Risk Myelodysplastic Syndrome

Recruiting
3
550
Europe, Canada, US, RoW
Tamibarotene, SY-1425, Placebo, Azacitidine
Syros Pharmaceuticals
Myelodysplastic Syndromes
11/24
02/29

Download Options